Document not yet available
ManualCOAMSDS
Folate Receptor 1 (FOLR1, also FRα/FBP/FOLR) is a GPI-anchored cell-surface glycoprotein and a clinically validated promising target for solid tumors. This protein binds folate with high affinity and mediates intracellular folate transport to meet the demand for one-carbon metabolism required for tumor cell proliferation. FRα is highly expressed in multiple solid tumors including ovarian cancer, endometrial cancer, non-small cell lung cancer and triple-negative breast cancer, while exhibiting very low expression in normal tissues and is spatially inaccessible to circulating molecules, leading to low off-target risks. It serves as a core target for the development of ADCs, therapeutic antibodies and folate-drug conjugates, and FRα-targeted ADCs have achieved marketing approval.
| Synonyms | FOLR-1, FBP, FOLR, FRα, FOLR1 |
|---|---|
| Protein Construction ＆ Source | •Recombinant Human FRα (Uniprot: P15328-1) Protein is expressed from HEK293 cells with Avi-His tag at the C-Terminus. It contains AA Arg 25 - Met 233. •The protein has a predicted MW of 28 kDa. The protein migrates as 35-40 kDa when calibrated against under reducing (R) condition (SDS-PAGE) due to glycosylation. |
| Endotoxin | < 0.1 EU per ug as determined by the LAL method. |
| Purity | > 95 % as determined by SEC-HPLC. |
| Concentration ＆ Formulation | •1.58 mg/mL •Filtered through a 0.22 μm filter, stored in 1x PBS, pH 7.4. |
| Transportation ＆ Storage | This product is shipped under low-temperature conditions. Avoid repeated freeze-thaw cycles during handling. •Protein solution can be stored at 2-8°C for 2-7 days. •Samples are stable for 3 months from date of receipt at -20℃ /-80℃. •Recommend to aliquot the protein into smaller quantities for optimal storage. |
| Target background | Folate Receptor 1 (FOLR1, also FRα/FBP/FOLR) is a GPI-anchored cell-surface glycoprotein and a clinically validated promising target for solid tumors. This protein binds folate with high affinity and mediates intracellular folate transport to meet the demand for one-carbon metabolism required for tumor cell proliferation. FRα is highly expressed in multiple solid tumors including ovarian cancer, endometrial cancer, non-small cell lung cancer and triple-negative breast cancer, while exhibiting very low expression in normal tissues and is spatially inaccessible to circulating molecules, leading to low off-target risks. It serves as a core target for the development of ADCs, therapeutic antibodies and folate-drug conjugates, and FRα-targeted ADCs have achieved marketing approval. |
|---|
For research use only. Not for use in diagnostic or therapeutic procedures.
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
